This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 27, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the pricing of its public offering of 15,000,000 shares of its common stock at
$21.40 per share. The offering is expected to close on or about
April 2, 2013. The gross proceeds from the offering will be approximately
$321.0 million. BioMed Realty expects to use the net proceeds of the offering to fund a portion of the purchase price for the recently announced, pending acquisition of Wexford Science & Technology, LLC, to repay a portion of the outstanding indebtedness under its unsecured line of credit and for other general corporate and working capital purposes. The acquisition of Wexford Science & Technology is subject to the receipt of lender, ground lessor and other third-party consents, waivers of rights of first offer and customary closing conditions, and there can be no assurances that the acquisition will close on the terms described, or at all. All of the shares are being sold by the company.
BioMed Realty has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Morgan Stanley & Co. LLC,
Raymond James & Associates, Inc., UBS Securities LLC, Wells Fargo Securities, LLC and KeyBanc Capital Markets Inc. are the joint book-running managers for the offering.
The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered shares, nor shall there be any sale of such shares in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or other jurisdiction. The offering of BioMed Realty's common stock will be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, New York 10014, at 1-866-718-1649 or by email at
Raymond James & Associates, Inc., 880 Carillon Parkway,
St. Petersburg, Florida 33716, by calling toll-free at 1-800-248-8863 or by email at
firstname.lastname@example.org; UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue,
New York, New York 10171, or toll-free at 1-888-827-7275; Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue,
New York, New York 10152, at 1-800-326-5897 or by email at
email@example.com; or KeyBanc Capital Markets Inc., Attention: Prospectus Delivery Department, 127 Public Square, 4th Floor,
Cleveland, Ohio 44114, telephone: 1-800-859-1783.
About BioMed Realty Trust
BioMed Realty delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.2 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of
Seattle, which have well-established reputations as centers for scientific research.